Dr KSS MD PhD (former columnist)

Author Bio

Dr KSS MD PhD (former columnist)
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS was a paid contributor to Stock Gumshoe, he has ceased contributing new content as of February, 2017. He agreed to our trading restrictions, chose his own topics, and his words and opinions are his own.

Author Archives

Special Update from $ARTH CEO Norchi

Arch Therapeutics ($ARTH) has withdrawn its 501(k) device-approval marketing application with the FDA. I spoke with CEO Terrence Norchi, MD, MBA, by phone this morning for clarification and to ask a few questions. Norchi explained that he regards Arch’s relationship with the FDA as “good and friendly” and wants to be cautious not to jeopardize […]

Tear Sheet: CohBar Inc. ($CWBR)

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for ourĀ Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Visit his Stock Gumshoe page for more.] Bacteria are prokaryotes. Animal cells, fungi and plants are eukaryotes. Prokaryotes tend to be acellular and […]

Cisco, Chang & Charlie Part 3

Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]

Oncotutorial

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

Long Idea of the Year

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

Quickster: Update on Corbus

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

Recent Author Comments

On Dr. KSS Liveblog: Noblecon 14
You certainly are. I resent what you have done. You are a monster and are not welcome on my threads. You have deeply and profoundly offended me and do not deserve the kindness I have shown you. You've flung a lot of shit tonight mister and caused a lot of [...]
On Dr. KSS Liveblog: Noblecon 14
It's utterly pathetic. The troublemaker in question wrote to Travis to stir up trouble between him and me and so now everyone in question is quite thoroughly up in arms. Thank you for that. I' ve had really a rough day exerting myself on behalf of.....no, [...]
On Dr. KSS Liveblog: Noblecon 14
The issue is purely a Thoreauvian one....give yourself over entirely to your fellow man and they deem you cheap and worthless. Thus I utterly bust my ass in SF providing night and day coverage and the board here degenerates into rancor, name-calling and Pa[...]
On Dr. KSS Liveblog: Noblecon 14
Placebo non-responders are not re-randomized. They were already randomized. They cross over into the therapy arm, which consists solely of placebo non-responders. It's the protocol NIMH is now using. The placebo and test drug therapy durations prior to end[...]
On Dr. KSS Liveblog: Noblecon 14
My sentiments precisely. Since lately people are so rancorous that everything i DARE to post incurs a need for 20 more posts to deal with the aftermath of trying to be helpful, I'm not posting any more for a few days. Stop expecting me to be other than hum[...]
On Dr. KSS Liveblog: Noblecon 14
Tenenbaum is CEO, not CFO, of Bellerophon.[...]
On Dr. KSS Liveblog: Noblecon 14
It wasn't directed at you or at anybody. It's just me stating that at certain kinds of tasks, I don't do well. I am not good at scheduling and organizing events, and don't feel comfortable when tasked with such. Just my nature. I am good at showing up and [...]
On Dr. KSS Liveblog: Noblecon 14
It's not screening applicants. Actually, I ran the trial design by my close friend Vasiliy Vlassov, MD, PhD, an internationally revered expert in trial design and trial analysis, and he said it's highly novel but ethically sound, just a very amped up adapt[...]
On Dr. KSS Liveblog: Noblecon 14
Something I've tried to convey to readers is that sometimes there are things I know are about to happen with companies where I can't reveal it....that I have been explicitly told to be keep quiet about it. This is one of those times with $APTO. A cluster o[...]
On Dr. KSS Liveblog: Noblecon 14
I honestly don't understand the question.[...]
On Dr. KSS Liveblog: Noblecon 14
Honestly, I don't think it's right or fair that I prepare all the content for the call and work myself as hard as I have this week but that I also have to be responsible for scheduling the call and absorbing ALL the feedback from those who don't want it wh[...]
On Dr. KSS Liveblog: Noblecon 14
I've still got a number of post-meeting follow-up things to do.....lists and lists, piles of business cards to respond to. My suggestion is that we move it to next week. We had spoken of trying it on Saturdays. My suggestion is Saturday, 10 Feb, at 1 pm ET[...]
On Dr. KSS Liveblog: Noblecon 14
https://www.fiercebiotech.com/biotech/mit-study-finds-14-trials-see-approvals-higher-than-first-thought?mkt_tok=eyJpIjoiT1RNNVpXRm1NalJrWkRCaSIsInQiOiJ6QyswRWYrNUJtWFhtSG0zWVJHODZTK2ZtK3pjb0diQ0RyY2VoRndPWFI1MndXYmVBMVYzc2NNZzhXcnVMVDJVb05YaWQxWGhwYlZkWldH[...]
On Dr. KSS Liveblog: Noblecon 14
Well, the two agents from Naurex and Vistagen aren't directly comparable: Naurex's drug is exclusively iv. But, yes, I think Singh would like shareholders to think of that as a template for the prospective future. It's fairly clear that beyond writing out [...]
On Dr. KSS Liveblog: Noblecon 14
Lumpy: $EBIO looks pretty good to me here. I'm not personally in it-----merely for lack of funds-----but I would personally hold on to it here even after a 50 percent run. Don't take that as formal advice, it's just what I would do. It's still way underval[...]
On Dr. KSS Liveblog: Noblecon 14
This could be any of us https://splinternews.com/how-to-not-die-in-america-1822555151/amp[...]
On Dr. KSS Liveblog: Noblecon 14
The trick here is that people tend to assume that when oncolytic viruses do their thing, that they shrink tumors by causing breakup of tumor cells (kind of like what bacteriophages do to bacteria). But that's only half right. Listen, when you shred tumor c[...]
On Dr. KSS Liveblog: Noblecon 14
They'd not be having an R&D day if there was not something positive to present and a way forward. I HAVE said for months I predict positive data in phase 2 despite the fact that things do look dodgy on first impression. No personal position in $HTBX at pre[...]
On Dr. KSS Liveblog: Noblecon 14
Ja...I met with the CEO last night and have been emailing with him this am. Think we're going to definitely run with this one this year. I want to poke around for a couple more weeks and review kallikrein pharmacology, but I suspect they are clasping at so[...]
On Dr. KSS Liveblog: Noblecon 14
Nice work, Curt. Proud of you. Folks I am travelling today....may not get to post much.[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.